A

Amgen

Makes biotech medicines for serious illnesses

Patient Access & Reimbursement Marketing Manager - Biosimilar

Full-TimePosted on 10/19/2026
$131.9k - $178.4k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Mid, Senior
Bachelor's, Master's, PhD, Associate's
Thousand Oaks, CA, USA
Remote
Growth & MarketingProduct Marketing

About the job

Requirements
  • A doctorate degree and 2 years of sales, marketing, market access, employer benefits, or payer experience; or a master's degree and 4 years of such experience; or a bachelor's degree and 6 years; or an associate's degree and 10 years; or a high school diploma or GED and 12 years.
  • Strong understanding of the U.S. healthcare access and payer landscape, including buy-and-bill and specialty pharmacy models, formulary coverage, utilization management requirements such as prior authorization and step therapy, reimbursement, and patient support services.
  • Experience in marketing, sales, patient access, or a related role in the pharmaceutical or biotechnology industry.
  • Experience developing and executing marketing programs, customer-facing materials, or field enablement initiatives.
  • Ability to synthesize brand priorities, customer and patient insights, market research, field feedback, and performance data into actionable recommendations and effective resources.
  • Experience collaborating with field teams and cross-functional partners, including Brand, Payer, Patient Support, Market Research, and Analytics, and building alignment and influencing outcomes without direct authority.
  • Experience working with external agencies and vendors to support the development and execution of marketing initiatives.
  • Experience managing budgets or components of budgets, including tracking spend, prioritizing investments, and resolving issues.
  • Project management and organizational skills, including independently managing multiple workstreams, timelines, and deliverables with attention to detail in a fast-paced environment.
  • Experience leveraging AI tools and effective prompting to improve insight synthesis, content development, and execution efficiency.
  • Written and verbal communication skills, including simplifying complex information for different audiences.
  • Initiative, curiosity, sound judgment, accountability, and openness to seeking and acting on feedback.
Responsibilities
  • Support development of patient access strategy and lead tactical planning for assigned brands.
  • Build an understanding of customer needs by working with Brand, Sales, and Payer teams.
  • Perform situational analysis by synthesizing insights from market research and analysis, field teams, and customers to identify patient access needs and improvement opportunities; recommend tactics or new access offerings based on findings.
  • Use feedback and results to assess tactics and recommend refinements.
  • Develop and execute tools, resources, and communications that bring patient access strategies to life for field teams, healthcare professionals, and patients, including customer-facing and patient marketing materials, multichannel content, speaker decks, and internal or external communications.
  • Lead marketing and communication materials through internal review and approval processes, coordinating cross-functional input and timely submission.
  • Listen to field needs and support effective use of access programs, tools, and communications.
  • Develop and deliver training on programs and resources for field teams and Key Account Managers, and support field staff by addressing questions through field calls, national sales or semester meetings, leadership calls, and other forums.
  • Serve as a resource to field teams on payer and access support services, and build relationships with field staff at all levels.
  • Partner with Brand Marketing, Medical, Market Research, Competitive Intelligence, Business Analytics, Sales Operations, and Sales Training to align patient access and reimbursement tactics and deliverables with brand priorities and the market landscape, and coordinate field readiness.
  • Partner with patient access and reimbursement teams, including HUB, Value & Access Insights, Co-pay, Field Reimbursement Specialists, and Patient Navigators, to align operational plans and execution with brand strategy and patient access needs.
  • Work with Legal, Regulatory, Compliance, and other internal partners to support compliant programs and materials.
  • Manage assigned projects and agency or vendor workstreams, including timelines, deliverables, budget inputs, and day-to-day coordination.
  • Manage budgets for assigned brands, including annual planning, tracking, issue resolution, and coordination with Finance and cross-functional partners.
  • Leverage enterprise-approved AI tools to enhance insight generation, content development, project management, and execution quality while maintaining appropriate compliance, privacy, and human oversight.
  • Identify opportunities to innovate and develop new AI-enabled tools, frameworks, and ways of working to improve the efficiency, effectiveness, and impact of patient access and reimbursement activities.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.